12-132624738-G-C
Variant summary
Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBS1BS2
The NM_006231.4(POLE):āc.6820C>Gā(p.Leu2274Val) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000538 in 1,613,742 control chromosomes in the GnomAD database, including 6 homozygotes. In-silico tool predicts a benign outcome for this variant. 14/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (ā ā ).
Frequency
Consequence
NM_006231.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -20 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.00269 AC: 409AN: 152226Hom.: 4 Cov.: 33
GnomAD3 exomes AF: 0.000877 AC: 220AN: 250994Hom.: 3 AF XY: 0.000751 AC XY: 102AN XY: 135740
GnomAD4 exome AF: 0.000313 AC: 457AN: 1461398Hom.: 2 Cov.: 30 AF XY: 0.000257 AC XY: 187AN XY: 727054
GnomAD4 genome AF: 0.00270 AC: 412AN: 152344Hom.: 4 Cov.: 33 AF XY: 0.00273 AC XY: 203AN XY: 74490
ClinVar
Submissions by phenotype
not specified Benign:5
Benign, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Dec 12, 2016 | - - |
Benign, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | May 06, 2018 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Aug 21, 2017 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital | Mar 04, 2025 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Feb 27, 2020 | - - |
not provided Benign:4
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | Mar 05, 2021 | This variant is associated with the following publications: (PMID: 22885699, 33256706) - |
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 04, 2025 | - - |
Likely benign, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, Amsterdam University Medical Center | - | - - |
Likely benign, no assertion criteria provided | clinical testing | Clinical Genetics, Academic Medical Center | - | - - |
Hereditary cancer-predisposing syndrome Benign:3
Benign, criteria provided, single submitter | clinical testing | Institute for Biomarker Research, Medical Diagnostic Laboratories, L.L.C. | Jan 20, 2025 | The missense variant NM_006231.4(POLE):c.6820C>G (p.Leu2274Val) has been reported to ClinVar as Benign/Likely benign with a status of (2 stars) criteria provided, multiple submitters, no conflicts (Variation ID 240622 as of 2025-01-02). There is a small physicochemical difference between leucine and valine, which is not likely to impact secondary protein structure as these residues share similar properties. The gene POLE has a low rate of benign missense variation as indicated by a high missense variants Z-Score of 2.65. The gene POLE contains 12 pathogenic missense variants, indicating that missense variants are a common mechanism of disease in this gene. For these reasons, this variant has been classified as Benign - |
Benign, criteria provided, single submitter | curation | Sema4, Sema4 | Jul 20, 2020 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 30, 2015 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Colorectal cancer, susceptibility to, 12 Benign:1
Benign, criteria provided, single submitter | clinical testing | KCCC/NGS Laboratory, Kuwait Cancer Control Center | Jul 07, 2023 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at